ZBNA
SMMT icon

Zions Bancorporation, National Association’s Summit Therapeutics SMMT Stock Holding History

Zions Bancorporation, National Association’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92K Buy
+132
New +$2.34K ﹤0.01% 1312

Other funds holding SMMT

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
WMP
Wealth Management Partners Tucson, Arizona $425M AUM 60.71% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Zions Bancorporation, National Association's SMMT Position: Q2 2026 in Review

Zions Bancorporation, National Association opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 132 shares worth $1.92K. The stake represents ﹤0.01% of the portfolio and ranks #1312 among its holdings.

43 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Zions Bancorporation, National Association held 132 shares of Summit Therapeutics worth $1.92K as of Q2 2026.
  • Summit Therapeutics was a new Zions Bancorporation, National Association position in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Zions Bancorporation, National Association's portfolio in Q2 2026, its #1312 holding.
  • 43 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Zions Bancorporation, National Association's 13F filing for Q2 2026, filed 31 Jul 2026.